Alexion shoots for fast review of Soliris successor using a PRV; Sandoz wades into medical cannabis business
→ Anxious to get their Soliris successor to the FDA, Alexion $ALXN is using one of its two priority review vouchers to shave four …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
